<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734524</url>
  </required_header>
  <id_info>
    <org_study_id>TMMU-BTC-004</org_study_id>
    <nct_id>NCT02734524</nct_id>
  </id_info>
  <brief_title>A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer</brief_title>
  <official_title>A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to explore if the combination of autologous NK cell&#xD;
      infusion and chemotherapy can increase the therapeutic efficiency in the treatment of&#xD;
      non-small cell lung cancer compared with chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Natural killer cells play an important role in the anti-tumor process mediated by innate&#xD;
      immunity. However, past researches showed dissatisfactory clinical outcome in clinicaltrials&#xD;
      using autologous NK cell infusion alone. With the expectation that the combination of&#xD;
      autologous NK cell infusion and chemotherapy may increase the therapeutic efficiency of&#xD;
      chemotherapy alone in cancer treatment, the investigators design and conduct this randomized&#xD;
      controlled trial in the treatment of non-small cell lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants responding to treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Response evaluation of treatment with chest CT scan is assessed by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival(PFS) time</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NK infusion+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment includes four cycles. For each cycle: Taxol and carboplatin will be given at the first week. Lymphodepletion will be conducted at the second week. Autologous NK cells will be infused at the third week. Each cycle includes four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive the same taxol and carboplatin in experimental arm without NK cell infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NK cells</intervention_name>
    <description>Natural killer cell infusion is an intervention between two arms. Dosage of infused cell &gt;1×10^9，q28d*4</description>
    <arm_group_label>NK infusion+chemotherapy</arm_group_label>
    <other_name>natural killer cell infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxol</intervention_name>
    <description>135-175mg/m2,q28d*4</description>
    <arm_group_label>NK infusion+chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>TAX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC=5,q28d*4</description>
    <arm_group_label>NK infusion+chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>Cis-platinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-small cell lung cancer must be diagnosed by pathology and staged as ⅢB or Ⅳ with&#xD;
             2009-UICC TNM staging system and operation is excluded due to medical reasons or&#xD;
             patient's will.&#xD;
&#xD;
          2. According to Response Evaluation Criteria in Solid Tumors(RECIST), at least one&#xD;
             measurable or evaluable nidus can be detected by chest CT.&#xD;
&#xD;
          3. ECOG score 0-1.&#xD;
&#xD;
          4. Gender is not limited, age from 18 years to 75 years.&#xD;
&#xD;
          5. Patients are expected to survive for more than 3 months by their physicians at the&#xD;
             time of enrollment.&#xD;
&#xD;
          6. Mental state is evaluated as normal.&#xD;
&#xD;
          7. Adequate cardiac function(LVEF≥40%, tested within one month) without heart diseases.&#xD;
&#xD;
          8. Hepatic and renal function were normal, biochemical criterion must meet the requests&#xD;
             below: white blood cell count≥2.5×10^9/L，platelet count≥100×10^9/L，hemoglobin≥90g/L,&#xD;
             serum bilirubin≤2 upper limit of normal(ULN), AST and ALT≤2 ULN(AST, ALT≤5ULN under&#xD;
             hepatic metastases), Bun≤2 ULN, serum creatinine≤2 ULN.&#xD;
&#xD;
          9. No other serious illnesses(e.g.,autoimmune disease, immunodeficiency, ect.).&#xD;
&#xD;
         10. Ability to give informed consent.&#xD;
&#xD;
         11. No other malignancies diagnosed.&#xD;
&#xD;
         12. Patients volunteer to participate in the research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria are not eligible for participation in the&#xD;
        study:&#xD;
&#xD;
          1. Frequent infection history and recent infection is uncontrolled.&#xD;
&#xD;
          2. Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi&#xD;
             anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure&#xD;
             syndrome&#xD;
&#xD;
          3. Concurrent use of systemic steroids or chronic use of immunosuppressant medications.&#xD;
             Recent or current use of inhaled steroids is not exclusionary. For additional details&#xD;
             regarding use of steroid and immunosuppressant medications.&#xD;
&#xD;
          4. Pregnancy and nursing females.&#xD;
&#xD;
          5. HIV infection.&#xD;
&#xD;
          6. Active hepatitis B or active hepatitis C.&#xD;
&#xD;
          7. Participation in a prior investigational study within 4 weeks prior to enrollment or&#xD;
             longer if required by local regulation. Participation in non-therapeutic research&#xD;
             studies is allowed.&#xD;
&#xD;
          8. Class III/IV cardiovascular disability according to the New York Heart Association&#xD;
             Classification.&#xD;
&#xD;
          9. Patients with a known history or prior diagnosis of other serious immunologic,&#xD;
             malignant or inflammatory disease.&#xD;
&#xD;
         10. Other situations we think not eligible for participation in the research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Qian, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Biotherapy Center of Southwest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Qian, MD, PhD</last_name>
    <phone>0086-023-68765461</phone>
    <email>cqian3184@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi Yang, PhD</last_name>
    <phone>0086-13206140093</phone>
    <email>Lystch@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southwest Hospital of Third Millitary Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Qian, PhD</last_name>
      <phone>008615086883400</phone>
      <email>cqian3184@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhi Yang, PhD</last_name>
      <phone>008613206140093</phone>
    </contact_backup>
    <investigator>
      <last_name>Cheng Qian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>November 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>January 20, 2018</last_update_submitted>
  <last_update_submitted_qc>January 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Shiqi Li</investigator_full_name>
    <investigator_title>Researcher of Biotherapy Center</investigator_title>
  </responsible_party>
  <keyword>Natural killer cells</keyword>
  <keyword>NSCLC</keyword>
  <keyword>NCT</keyword>
  <keyword>Combined therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

